Last edition
News about "autoimmune diseases "
US-based biotechnology company Kaigene has signed an exclusive global licensing agreement with South Korean biopharmaceutical giant Celltrion to develop and commercialise two of its nonclinical-stage antibody assets, KG006 and KG002.
Autoimmune Diseases | 04/11/2025 | By Dineshwori
EVOQ Therapeutics Receives USD 2 Million NIH Grant to Develop Therapies for Celiac Disease
The NIH award represents a significant endorsement of EVOQ's ground-breaking approach to harnessing the power of the immune system to treat and prevent autoimmune diseases.
Autoimmune Diseases | 14/10/2025 | By Dineshwori | 138
Bristol Myers Squibb Acquires Orbital Therapeutics
The acquisition of Orbital Therapeutics by Bristol Myers Squibb includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogramme cells in vivo with potential best-in-class profile for autoimmune diseases.
Autoimmune Diseases | 13/10/2025 | By Dineshwori
China's Leads Biolabs Wins FDA Nod to Begin First-in-Human Trial of Novel Autoimmune Therapy
The US Food and Drug Administration (FDA) has approved Leads Biolabs’ first-in-human Investigational New Drug (IND) application for LBL-047, a novel therapeutic candidate for the treatment of autoimmune diseases such as systemic lupus erythematosus, dermatomyositis, IgA nephropathy and Sjögren's syndrome.
Autoimmune Diseases | 22/09/2025 | By Dineshwori | 182
Onco3R Therapeutics Secures Approval to Launch First-in-Human Trial of SIK3 Inhibitor O3R-5671
Onco3R Therapeutics is expected to start enrolling subjects for the first-in-human trial of SIK3 inhibitor O3R-5671 over the coming weeks, with dosing of the first subject anticipated later in September.
Autoimmune Diseases | 04/09/2025 | By Dineshwori | 171
AbbVie to Acquire Nimble Therapeutics to Expand its Immunology Pipeline
AbbVie will acquire Nimble's peptide synthesis, screening, and optimization platform, which uses proprietary technology to help drive rapid discovery and optimization of peptide candidates for a range of targets.
Autoimmune Diseases | 18/12/2024 | By Aishwarya | 491
AbbVie and FutureGen to Develop Next-Gen Therapy for Inflammatory Bowel Disease
AbbVie has signed a license agreement with FutureGen Biopharmaceutical to develop FG-M701, a next-generation TL1A antibody for the treatment of IBD currently in preclinical development.
Autoimmune Diseases | 14/06/2024 | By Aishwarya | 296
Vertex Signs Agreement to Acquire Alpine Immune Sciences
Vertex Pharmaceuticals has signed a definitive agreement with Alpine Immune Sciences, a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
Autoimmune Diseases | 11/04/2024 | By Aishwarya | 581
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy